Table S1.
Comorbidities, baseline co-medications and COPD classifications in each study cohort
| Patient characteristics | n (%)
|
P-valuee | |
|---|---|---|---|
| Similar-devices cohort (n=8,225) | Mixed-devices cohort (n=8,225) | ||
| Comorbidities | |||
| Asthmaa | 1,870 (22.7) | 1,926 (23.4) | 0.17 |
| Asthma (active)a,c | 896 (10.9) | 896 (10.9) | NA |
| Diabetesa | 1,388 (16.9) | 1,356 (16.5) | 0.487 |
| Oral thrushb | 49 (0.6) | 63 (0.8) | 0.187 |
| Rhinitisa | 677 (8.2) | 584 (7.1) | 0.006 |
| Rhinitis (active)b,d | 345 (4.2) | 331 (4.0) | 0.579 |
| Eczemaa | 1,162 (14.1) | 1,143 (13.9) | 0.665 |
| Eczema (active)b,d | 223 (2.7) | 181 (2.2) | 0.034 |
| Cardiovascular diseasea | 2,811 (34.2) | 2,817 (34.3) | 0.918 |
| Heart failurea | 409 (5.0) | 404 (4.9) | 0.918 |
| Ischemic heart diseasea | 1,693 (20.6) | 1,719 (20.9) | 0.605 |
| Hypertensionb | 1,247 (15.2) | 1,192 (14.5) | 0.223 |
| Gastroesophageal reflux diseasea | 586 (7.1) | 586 (7.1) | .0.99 |
| GERD (active)b,d | 400 (4.9) | 419 (5.1) | 0.49 |
| Osteoporosisa | 451 (5.5) | 512 (6.2) | 0.038 |
| Pneumoniab | 75 (0.9) | 113 (1.4) | 0.006 |
| Anxiety, depression | 373 (4.5) | 381 (4.6) | 0.763 |
| Charlson comorbidity index scoreb | |||
| 0 | 5,610 (68.2) | 5,657 (68.8) | 0.477 |
| 1–4 | 1,756 (21.4) | 1,736 (21.1) | |
| 5–9 | 318 (3.9) | 334 (4.1) | |
| ≥ 10 | 541 (6.6) | 498 (6.1) | |
| Co-medications | |||
| NSAIDsc | 3,368 (41.0) | 3,474 (42.2) | 0.087 |
| Paracetamolc | 3,129 (38.0) | 3,229 (39.3) | 0.103 |
| Beta blockersc | 1,080 (13.1) | 1,016 (12.4) | 0.127 |
| Statinsc | 2,518 (30.6) | 2,640 (32.1) | 0.027 |
| Other measures of COPD severity | |||
| mMRC score (closest to index date) | <0.001 | ||
| Non-missing | 6,572 (79.9) | 6,654 (80.9) | |
| 0–1 | 3,863 (58.8) | 3,765 (56.6) | |
| ≥ 2 | 2,709 (41.2) | 2,889 (43.4) | |
| GOLD grade (closest to index date) | Not tested | ||
| Non-missing | 7,726 (93.9) | 7,791 (94.7) | |
| A | 717 (9.3) | 717 (9.2) | |
| B | 4,796 (62.1) | 4,788 (61.5) | |
| C | 1,903 (24.6) | 1,918 (24.6) | |
| D | 310 (4.0) | 368 (4.7) | |
Notes:
With a diagnostic code recorded at any time prior to or at the last extraction date;
calculated for the baseline period including the last extraction date;
asthma patients exclude those with asthma resolved codes;
includes prescriptions to treat the comorbidity within the baseline period and at the last extraction date;
P-values are from conditional logistic regression models; GOLD grade was not compared between cohorts as there was a large amount of missing data.
Abbreviations: mMRC, modified Medical Research Council; GOLD, Global initiative for chronic Obstructive Lung Disease – groups based on 2015 GOLD Strategy; GERD, gastroesophageal reflux disease; NSAIDs, non-steroidal anti-inflammatory drugs; NA, not applicable (as variable was used for matching).